CPC A61K 36/28 (2013.01) [A61K 8/34 (2013.01); A61K 8/345 (2013.01); A61K 8/361 (2013.01); A61K 8/375 (2013.01); A61K 8/41 (2013.01); A61K 8/678 (2013.01); A61K 8/8152 (2013.01); A61K 8/922 (2013.01); A61K 8/97 (2013.01); A61K 8/9789 (2017.08); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 31/192 (2013.01); A61K 36/185 (2013.01); A61K 36/63 (2013.01); A61K 36/886 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/18 (2013.01); A61K 47/22 (2013.01); A61K 47/32 (2013.01); A61K 47/44 (2013.01); A61P 17/02 (2018.01); A61P 17/06 (2018.01); A61Q 17/04 (2013.01); A61Q 19/00 (2013.01); A61Q 19/005 (2013.01); A61Q 19/007 (2013.01); A61K 2236/37 (2013.01)] | 9 Claims |
1. A method for treatment of skin discomfort caused by skin inflammation, atopic dermatitis, psoriasis, urticaria, radiotherapy induced atopic dermatitis, UV and/or oxidation skin and/or thirst or second degree burn and damage associated with skin moisture disbalance, the method comprising applying an effective amount of a topical composition;
wherein the composition comprises: about 8.76% Caprylic/capric triglyceride, 5.64% Aloe barbadensis leaf juice, 0.94% stearic acid, 0.52% glycerol monostearate, 0.25% triethanolamine, 0.4% vitamin E, 3.33% Olive europaea fruit oil, 3.33% glycerol, 0.6% acrylates/C10-30 alkyl acrylate crosspolymer, 0.07% Calendula officinalis flower extract, 0.8% phenoxyethanol, and water,
wherein the composition further comprises 0.75-1% of a Cannabis sativa extract in decarboxylated form and containing 0.25% of CBD, and 0.75-1% of the Cannabis sativa extract in non-carboxylated form and containing 0.25% CBDA, wherein the Cannabis sativa extract comprises about 80% of CBDA from the total cannabinoids, and THC is less than 0.1%.
|